Secondary Logo

Journal Logo

Most Popular Articles

Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia

Singh, Arun; Gopal, Srihari; Kim, Edward; More

International Clinical Psychopharmacology. 33(4):213-216, July 2018.

The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies

Weiss, Catherine; Weiller, Emmanuelle; Baker, Ross A.; More

International Clinical Psychopharmacology. 33(5):255-260, September 2018.

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies

Earley, Willie; Durgam, Suresh; Lu, Kaifeng; More

International Clinical Psychopharmacology. 32(6):319-328, November 2017.

Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate

Montalvo, Itziar; Ortega, Laura; López, Xavi; More

International Clinical Psychopharmacology. 28(1):46-49, January 2013.

A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan

Higuchi, Teruhiko; Kamijima, Kunitoshi; Nakagome, Kazuyuki; More

International Clinical Psychopharmacology. 31(1):8-19, January 2016.

Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics

Kwon, Jun Soo; Kim, Sung Nyun; Han, Jaewook; More

International Clinical Psychopharmacology. 30(6):320-328, November 2015.

Results from a drug utilization study of extended release quetiapine fumarate prescribed by psychiatrists as treatment for major depressive disorder in selected countries in the European Union

Brody, Robert S.; Liss, Charles L.; Wray, Heather; More

International Clinical Psychopharmacology. 33(2):59-65, March 2018.

Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials

Thase, Michael E.; Edwards, John; Durgam, Suresh; More

International Clinical Psychopharmacology. 32(5):281-288, September 2017.

Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder

Woo, Young Sup; Bahk, Won-Myong; Park, Young-Min; More

International Clinical Psychopharmacology. 31(5):275-286, September 2016.

Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis

Gartlehner, Gerald; Hansen, Richard A.; Carey, Timothy S.; More

International Clinical Psychopharmacology. 20(2):59-69, March 2005.

Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder

Fineberg, Naomi A.; Baldwin, David S.; Drummond, Lynne M.; More

International Clinical Psychopharmacology. 33(6):334-348, November 2018.

Show: